Unity Total Current Liabilities from 2010 to 2024
| UBX Stock | USD 1.21 0.02 1.68% |
Total Current Liabilities | First Reported 2016-12-31 | Previous Quarter 8.8 M | Current Value 8.8 M | Quarterly Volatility 4.5 M |
Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.5 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 1.07. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.
Unity | Total Current Liabilities |
Latest Unity Biotechnology's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Unity Biotechnology over the last few years. Total Current Liabilities is an item on Unity Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Unity Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Unity Biotechnology's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Unity Total Current Liabilities Regression Statistics
| Arithmetic Mean | 9,357,455 | |
| Geometric Mean | 7,408,430 | |
| Coefficient Of Variation | 67.08 | |
| Mean Deviation | 5,685,746 | |
| Median | 7,840,000 | |
| Standard Deviation | 6,276,732 | |
| Sample Variance | 39.4T | |
| Range | 15.9M | |
| R-Value | 0.77 | |
| Mean Square Error | 17.3T | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | 1,081,042 | |
| Total Sum of Squares | 551.6T |
Unity Total Current Liabilities History
About Unity Biotechnology Financial Statements
Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 7.8 M | 14.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.